HR 2554 - Lower Drug Costs for Families Act

Overview

Bill Number: HR 2554

Title: Lower Drug Costs for Families Act

Status: Introduced in House

Introduced: April 01, 2025

Purpose and Intent

The Lower Drug Costs for Families Act aims to address the rising cost of prescription drugs in the United States. The bill's primary goal is to provide relief to American families struggling with the high prices of essential medications. By implementing a series of regulatory and market-based reforms, the legislation seeks to increase competition, transparency, and affordability in the pharmaceutical industry.

Key Provisions

• Authorizes the Secretary of Health and Human Services to negotiate directly with drug manufacturers to set maximum prices for certain high-cost prescription drugs covered under Medicare Part D
• Requires drug companies to provide rebates to the government if they increase prices faster than the rate of inflation
• Eliminates the non-interference clause that previously prohibited the government from negotiating drug prices
• Caps out-of-pocket costs for Medicare beneficiaries at $2,000 per year for prescription drugs
• Establishes a new program to provide free or low-cost generic drugs to uninsured individuals with household incomes below 400% of the federal poverty level

Affected Parties and Impacts

The Lower Drug Costs for Families Act would primarily benefit Medicare beneficiaries and uninsured individuals by reducing their out-of-pocket expenses for prescription drugs. Drug manufacturers would face increased government oversight and price controls, which could impact their revenue and profit margins. The legislation could also have broader effects on the healthcare system, potentially leading to lower overall drug spending and reduced insurance premiums.

Procedural and Timeline Considerations

The Lower Drug Costs for Families Act was introduced in the House of Representatives on April 1, 2025. It has been referred to the House Committee on Energy and Commerce, which will likely hold hearings and mark-up sessions before the bill can be considered by the full House. If passed by the House, the bill would then move to the Senate for further consideration. The ultimate timeline for the legislation's passage and enactment into law remains uncertain, as it will depend on the political dynamics and legislative priorities of the 117th Congress.